TAVI (Transcatheter aortic valve implantation)

Women have long been underrepresented in TAVR trials. This article explores the DEDICATE trial’s sex-specific outcomes after TAVI and SAVR, revealing differences in early stroke risk, procedural challenges, and one-year survival in men and women with aortic stenosis.

Register for free to this webinar on Monday 13 April at 5:00pm with O. Demir, T. Nestelberger and T. Rheude and review the contemporary evidence on TAVI durability, and much more!

Aortic stenosis (AS) is the most common valvular heart disease leading to intervention. It is characterized by progression from leaflet thickening and calcification to significant haemodynamic stenosis which results in disease-specific symptoms and physical limitations as well as poor prognosis and impaired quality of life if...

A 79-year-old patient previously treated with surgical aortic valve replacement was referred after an episode of acute cardiac decompensation. Although clinically stabilised, further evaluation revealed degeneration of the bioprosthesis, and mixed aortic valve pathology.

This case focuses on the diagnostic assessment and the strategic considerations guiding the...

The 6-year results of the Evolut Low Risk trial confirm the absence of significant differences in the composite primary endpoint between TAVR and surgery, but introduce an important nuance: the first signal of increased valve reintervention in the TAVR arm within this trial.

Alex Sticchi interviews Adam B. Greenbaum on the PROTECT head-to-head trial, comparing the new full-body Emboliner device with the first-generation Sentinel during TAVR, as presented at ACC.26 in New Orleans.

Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.

A 71-year-old low-risk patient with symptomatic severe aortic stenosis and preserved ventricular function presents with progressive dyspnoea and chest pain. With long life expectancy, the choice of treatment demands careful interdisciplinary planning. How would you treat?

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2026 Scientific Sessions #ACC26

Patients with severe symptomatic aortic stenosis and small annuli—most often women—face higher risks of elevated gradients, patient–prosthesis mismatch and early valve failure after TAVI, with added challenges for future coronary access and redo procedures, particularly in younger populations.

While previous studies have mainly compared supra-annular balloon- and...

This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...

This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.

This session offers an expert overview of transcatheter electrosurgery and leaflet modification techniques for aortic valve interventions, focusing on TAV-in-SAV scenarios. It reviews patient selection, procedural setup, and material preparation, with detailed step-by-step guidance on BASILICA and UNICORN techniques, supported by recorded cases and troubleshooting strategies...

This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...

This session delves into the comprehensive management of ischemic heart disease in patients undergoing transcatheter aortic valve implantation (TAVI). It highlights the critical importance of maintaining coronary access post-TAVI and explores how various valve designs affect coronary accessibility, particularly in cases involving valve-in-valve (TAV-in-TAV) procedures, guiding...

This comprehensive session on redo Transcatheter Aortic Valve Implantation (TAVI) covers critical aspects beyond coronary obstruction risk, including detailed pre-procedural analysis, valve sizing, and innovative procedural techniques such as leaflet modification and optimal angle placement. Post-procedural considerations like antithrombotic therapy and patient-prosthesis mismatch are also thoroughly...

Explore the prevention and management of complications arising from transcatheter interventions in structural heart disease through challenging case analyses. This session presents real-world scenarios addressing complications encountered during TAVI, mitral, and tricuspid procedures, highlighting strategies to anticipate and manage these critical events effectively.

This expert-led session offers an in-depth review of evolving clinical practices in aortic valve disease treatment, emphasizing the potential of the transcarotid approach as a primary alternative access route. It compares current strategies including TAVI, surgical aortic valve replacement (SAV), TAV-in-SAV, and TAVI explantation, while addressing...

This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...

Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...